GSK (GSK.L/​​​GSK.N): Revisiting Elliott’s Letter and What Remains Unanswered

GSK (GSK.L/​​​​GSK.N):  Bluebell Capital Partners Aligns with Elliott

Unilever/GSK Heathcare: Ballsy, but Doable

GSK (GSK.L) Why Activism Might Be the Right Medicine.

GSK (GSK.L/​GSK.N) Elliot Goes Public with Campaign Demands

GSK (GSK.L/GSK.N) Activists Likely to Question the Spin-Off

Global Special Situations & Strategy, SR Services Ltd

David Lepper

Global Special Situations & Strategy

SR Services Ltd

SR Services provides Strategic Knowledge and Solutions services for Family Offices and Corporate Business. 

We deliver this via advisory services, strategic planning, opportunity analysis/sourcing, as well as solution implementation. 

Whilst, we create intellectual discipline and operational leverage for your projects or daily activities, our ultimate objective is to empower whilst enhancing your decision making. 

Strategic Knowledge and Solutions

Event-Driven

<ul>
<li>
GSK has issued their response to Elliot’s letter, released 1st July 2021. The content of the response in our view reveals a lack of commitment, and a rather overly defensive stance suggesting GSK have been caught off guard by the letter. </li>
<li>
We discuss what investors (and GSK) should prepare for next. We sense whilst support is being named by GSK certain lines that have been laid out by investors, shareholders, and activists. These lines are set to be tested in the coming months. We discuss the key points and areas where named support may be at risk. We specifically, detail what investors and "long-standing" shareholders might wish to prepare for next from both GSK and Elliot. </li>
<li>The Silver Lining to all this: The one thing which is positive from this response is that GSK has confirmed that potential conditions are now present to achieve a higher share price in the coming months.</li>
</ul>



GSK has issued their response to Elliot’s letter, released 1st July 2021. The content of the response in our view reveals a lack of commitment, and a rather overly defensive stance suggesting GSK have been caught off guard by the letter. 

We discuss what investors (and GSK) should prepare for next. We sense whilst support is being named by GSK certain lines that have been laid out by investors, shareholders, and activists. These lines are set to be tested in the coming months. We discuss the key points and areas where named support may be at risk. We specifically, detail what investors and "long-standing" shareholders might wish to prepare for next from both GSK and Elliot. 
The Silver Lining to all this: The one thing which is positive from this response is that GSK has confirmed that potential conditions are now present to achieve a higher share price in the coming months.


Glaxosmithkline Pharmaceuticals (GLXO IN)

Glaxosmithkline Consumer Healthcare (SKB IN)

GSK (GSK.L/​​GSK.N) Fails to Impress, in Their Response to Elliot

GlaxoSmithKline PLC

GSK (GSK.L/GSK.N) Fails to Impress, in Their Response to Elliot

GlaxoSmithKline PLC

GSK (GSK.L/​​GSK.N) Fails to Impress, in Their Response to Elliot

GSK (GSK.L/GSK.N) Fails to Impress, in Their Response to Elliot